The World Health Organization launched the Global Program to Eliminate Lymphatic Filariasis in 2000 to map endemic areas and treat entire at-risk populations with the following mass drug administration regimens: albendazole (400 mg) alone twice per year for areas co-endemic with loiasis, ivermectin (200 mcg / kg) and albendazole (400 mg) annually in areas with onchocerciasis, and diethylcarbamazine (DEC) (6 mg / kg) and albendazole (400 mg) plus ivermectin (200 mcg / kg) in some settings, annually in areas without onchocerciasis or loiasis.